What is enGene Holdings Cash And Cash Equivalents?
enGene Holdings's quarterly cash and cash equivalents
increased
from Jul. 2023 ($37.59 Mil) to Oct. 2023 ($81.52 Mil) and
increased
from Oct. 2023 ($81.52 Mil) to Jan. 2024 ($85.65 Mil).
enGene Holdings's annual cash and cash equivalents
increased
from Oct. 2021 ($11.02 Mil) to Oct. 2022 ($20.43 Mil) and
increased
from Oct. 2022 ($20.43 Mil) to Oct. 2023 ($81.52 Mil).
enGene Holdings Cash And Cash Equivalents Historical Data
The historical data trend for enGene Holdings's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Holdings Cash And Cash Equivalents Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
enGene Holdings (NAS:ENGN) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
enGene Holdings Cash And Cash Equivalents Related Terms
Thank you for viewing the detailed overview of enGene Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
enGene Holdings (enGene Holdings) Business Description
7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9
Website
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENGN has been successfully added to your 